Paper Details

  1. Home
  2. Paper Details

The ATTAIN trials: efficacy and safety of telavancin compared with vancomycin for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia.

Author: BarriereSteven L

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Telavancin, a once-daily injectable antimicrobial, is a new treatment option for hospital-acquired bacterial pneumonia (HABP) caused by susceptible Staphylococcus aureus (including MRSA). It is noninferior to vancomycin but requires caution in patients with moderate-to-severe renal impairment.
Paper Details　
Original Abstract of the Article :
Hospital-acquired bacterial pneumonia (HABP) is the second most common nosocomial infection in the USA and the leading cause of mortality among hospital-acquired infections. An increasing proportion of HABP cases are the result of infection with methicillin-resistant Staphylococcus aureus (MRSA). Te...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.2217/fmb.14.4

データ提供：米国国立医学図書館（NLM）

Telavancin: A New Weapon Against Hospital-Acquired Pneumonia

Hospital-acquired bacterial pneumonia (HABP) is a serious infection that can occur in hospitalized patients. Telavancin is a new antibiotic that shows promise as a treatment for HABP, particularly those caused by methicillin-resistant Staphylococcus aureus (MRSA). This study compares the efficacy and safety of telavancin to vancomycin, the current standard of care for HABP, in two large clinical trials (ATTAIN). The researchers aim to establish the non-inferiority of telavancin to vancomycin and assess its safety profile.

Telavancin: A New Era in Treating Hospital-Acquired Pneumonia

The ATTAIN trials demonstrate that telavancin is non-inferior to vancomycin in treating HABP, including those caused by MRSA. Telavancin exhibited a similar safety profile to vancomycin, except for an increased mortality risk in patients with moderate-to-severe renal impairment. This finding highlights the importance of careful patient selection and monitoring when using telavancin, particularly in those with compromised kidney function. The study's results are significant as they offer a new therapeutic option for treating HABP, a serious infection.

Understanding Telavancin: A New Path Through the Sands

This research provides important information about the use of telavancin for treating HABP. While telavancin shows promise as an effective alternative to vancomycin, it's crucial to understand its potential risks, especially in patients with kidney problems. As Dr. Camel, I encourage everyone to stay informed about antibiotic resistance and the latest advancements in treating infections. Prompt diagnosis, appropriate treatment, and adherence to prescribed medication are vital for combating these serious health challenges.

Dr.Camel's Conclusion

This study provides valuable data on the efficacy and safety of telavancin compared to vancomycin for treating hospital-acquired bacterial pneumonia. The findings support the use of telavancin as a treatment option, particularly for infections caused by MRSA, but caution is warranted in patients with moderate-to-severe renal impairment.

Date :
  1. Date Completed 2015-01-23
  2. Date Revised 2018-12-02
Further Info :

Pubmed ID

24450506

DOI: Digital Object Identifier

10.2217/fmb.14.4

Related Literature

Article Analysis
・Effects of telavancin injection
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.